[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2018000430A1 - Compuesto de hidroxitriazina y uso médico relacionado. - Google Patents

Compuesto de hidroxitriazina y uso médico relacionado.

Info

Publication number
CL2018000430A1
CL2018000430A1 CL2018000430A CL2018000430A CL2018000430A1 CL 2018000430 A1 CL2018000430 A1 CL 2018000430A1 CL 2018000430 A CL2018000430 A CL 2018000430A CL 2018000430 A CL2018000430 A CL 2018000430A CL 2018000430 A1 CL2018000430 A1 CL 2018000430A1
Authority
CL
Chile
Prior art keywords
medical use
related medical
compound
hydroxytriazine
hydroxytriazine compound
Prior art date
Application number
CL2018000430A
Other languages
English (en)
Inventor
Ikuo Mitani
Masaki Yamashita
Yutaro Hirono
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2018000430A1 publication Critical patent/CL2018000430A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTO DERIVADO DE HIDROXITRIAZINA, INHIBIDOR DE MPGES-1; COMPOSICION FARMACEUTICA; AGENTE TERAPEUTICO O PROFILACTICO; METODO PARA INHIBIR MPGES-1; METODO PARA TRATAR O PREVENIR; Y SU USO PARA LA PROFILAXIS O TRATAMIENTO DEL DOLOR, REUMATISMO, FIEBRE, OSTEOARTRITIS, ARTERIOSCLEROSIS, ENFERMEDAD DE ALZHEIMER, ENTRE OTROS.
CL2018000430A 2015-08-17 2018-02-16 Compuesto de hidroxitriazina y uso médico relacionado. CL2018000430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015160284 2015-08-17

Publications (1)

Publication Number Publication Date
CL2018000430A1 true CL2018000430A1 (es) 2018-08-03

Family

ID=58052084

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000430A CL2018000430A1 (es) 2015-08-17 2018-02-16 Compuesto de hidroxitriazina y uso médico relacionado.

Country Status (19)

Country Link
US (3) US20170057943A1 (es)
EP (2) EP4046991A1 (es)
JP (4) JP2017039714A (es)
KR (1) KR20180037270A (es)
CN (1) CN108137515B (es)
AR (1) AR105711A1 (es)
AU (1) AU2016309337B2 (es)
BR (1) BR112018001809A2 (es)
CA (1) CA2992410A1 (es)
CL (1) CL2018000430A1 (es)
CO (1) CO2018002516A2 (es)
IL (1) IL257559B (es)
MX (1) MX2018002044A (es)
PE (1) PE20180951A1 (es)
PH (1) PH12018500181A1 (es)
SG (1) SG11201800698VA (es)
TW (1) TWI704139B (es)
WO (1) WO2017030115A1 (es)
ZA (1) ZA201801134B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992410A1 (en) * 2015-08-17 2017-02-23 Japan Tobacco Inc. Hydroxytriazine compounds and pharmaceutical use thereof
WO2017073709A1 (ja) * 2015-10-29 2017-05-04 あすか製薬株式会社 ピリミジン誘導体
RU2648181C1 (ru) * 2017-05-25 2018-03-22 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения нейроретинопатии вследствие тяжелой преэклампсии
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
TW202409037A (zh) * 2022-07-06 2024-03-01 日商Ａｓｋａ製藥股份有限公司 嘧啶衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2488032B1 (en) * 2009-09-23 2016-11-02 Albert Einstein College of Medicine, Inc. Prostaglandin transporter inhibitors and uses thereof
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CA2992410A1 (en) * 2015-08-17 2017-02-23 Japan Tobacco Inc. Hydroxytriazine compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
US20240076278A1 (en) 2024-03-07
AU2016309337B2 (en) 2021-03-04
JP2017039714A (ja) 2017-02-23
BR112018001809A2 (pt) 2018-09-18
CN108137515A (zh) 2018-06-08
CA2992410A1 (en) 2017-02-23
CO2018002516A2 (es) 2018-05-31
AR105711A1 (es) 2017-11-01
CN108137515B (zh) 2021-07-06
JP2024019449A (ja) 2024-02-09
SG11201800698VA (en) 2018-03-28
WO2017030115A1 (ja) 2017-02-23
JP2020193235A (ja) 2020-12-03
JP2022163169A (ja) 2022-10-25
PH12018500181A1 (en) 2018-07-30
EP4046991A1 (en) 2022-08-24
IL257559B (en) 2021-07-29
EP3339296A4 (en) 2019-01-23
US20170057943A1 (en) 2017-03-02
PE20180951A1 (es) 2018-06-11
IL257559A (en) 2018-04-30
EP3339296A1 (en) 2018-06-27
RU2018109220A (ru) 2019-09-19
US20210024486A1 (en) 2021-01-28
ZA201801134B (en) 2019-07-31
RU2018109220A3 (es) 2019-11-15
AU2016309337A1 (en) 2018-02-01
KR20180037270A (ko) 2018-04-11
TW201718524A (zh) 2017-06-01
MX2018002044A (es) 2018-04-13
TWI704139B (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2024010140A (es) Nuevos metodos.
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
PH12016502352A1 (en) Pharmaceutical composition
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
CL2017002229A1 (es) Inhibidores de bace1.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.